Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00526838
Show Display Options
Rank Status Study
1 Terminated Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
Conditions: Cancer;   Lymphoma
Intervention: Drug: XL228

Indicates status has not been verified in more than two years